InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Friday, 10/20/2017 7:55:37 AM

Friday, October 20, 2017 7:55:37 AM

Post# of 3878
RHB-104 Crohn’s P3 trial and CELG - GED-301 failure

With GED-301 failure, RHB-104 becomes front runner as it is expected to announce P3 topline results by Q3-2018

The entire company becomes attractive to CELG in I&I segment


http://www.investopedia.com/news/celgenes-710-million-bad-bet-drags-shares-lower/

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News